Bleichroeder LP Reports New 6.86% Stake in Ernexa Therapeutics Inc.

On May 14, 2026, Bleichroeder LP, along with Bleichroeder Holdings LLC and Andrew Gundlach, filed a Schedule 13G reporting a new 6.86% ownership stake in Ernexa Therapeutics Inc. (ERNA). The reporting persons beneficially own 80,000 shares of common stock as of the event date on March 31, 2026. This position represents a significant increase from a previous 0% holding. The filing also notes that Bleichroeder holds warrants that are currently subject to a 4.99% exercise limitation. If this limitation were not in place, the reporting persons would be deemed to beneficially own a total of 160,000 shares, which would represent approximately 12.84% of the issuer's outstanding common stock. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. Andrew Gundlach serves as the President and CEO for the entity filers.